On Monday, Denali Therapeutics Inc (NASDAQ: DNLI) was 3.64% up from the session before settling in for the closing price of $15.68. A 52-week range for DNLI has been $10.57 – $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 260.06% over the last five years. When this article was written, the company’s average yearly earnings per share was at -11.64%. With a float of $125.73 million, this company’s outstanding shares have now reached $142.63 million.
The firm has a total of 422 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Denali Therapeutics Inc stocks. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.01%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.81% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
You can see what Denali Therapeutics Inc (DNLI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.59 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 1.46 million was better than the volume posted last year of 1.27 million. As of the previous 9 days, the stock’s Stochastic %D was 96.86%. Additionally, its Average True Range was 1.07.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 36.39%, which indicates a significant decrease from 99.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.77% in the past 14 days, which was lower than the 75.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.41, while its 200-day Moving Average is $22.39. Now, the first resistance to watch is $16.48. This is followed by the second major resistance level at $16.70. The third major resistance level sits at $17.14. If the price goes on to break the first support level at $15.82, it is likely to go to the next support level at $15.38. Should the price break the second support level, the third support level stands at $15.16.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are 145,242K outstanding shares of the company, which has a market capitalization of 2.36 billion. As of now, sales total 0 K while income totals -422,770 K. Its latest quarter income was 0 K while its last quarter net income were -114,750 K.
